Skip to main content

Table 1 Tumor and normal tissue distribution at 24 h post-injection of 111In- or 64Cu-DOTA-trastuzumab Fab

From: A comparison of 111In- or 64Cu-DOTA-trastuzumab Fab fragments for imaging subcutaneous HER2-positive tumor xenografts in athymic mice using microSPECT/CT or microPET/CT

 

Percent injected dose/g a, b, c

Tissue

111 In-DOTA-trastuzumab

Fab

64 Cu-DOTA-trastuzumab

Fab

Blood

0.42 ± 0.08

1.40 ± 0.16

Heart

0.92 ± 0.06

2.42 ± 0.39

Lungs

0.80 ± 0.14

4.86 ± 0.57

Liver

3.13 ± 0.16

8.52 ± 0.81

Kidneys

62.85 ± 6.45

57.00 ± 7.09

Stomach

0.58 ± 0.05

3.41 ± 0.22

Intestines

0.61 ± 0.06

4.76 ± 0.41

Spleen

2.25 ± 0.13

5.00 ± 0.27

Muscle

0.78 ± 0.31

0.75 ± 0.06

Tumor

4.00 ± 0.91

5.01 ± 1.20

  1. 111In- or 64Cu-DOTA-trastuzumab Fab in athymic mice bearing subcutaneous MDA-MB-361 human breast cancer xenografts. aValues shown are mean ± SD (n = 4). bSignificantly different for 111In- and 64Cu-DOTA-trastuzumab Fab for blood, heart, lungs, liver, stomach, intestines, and spleen (all P < 0.001). cNot significantly different for 111In- and 64Cu-DOTA-trastuzumab Fab for kidneys, muscle, or tumor (P > 0.05).